CARLSBAD, Calif.--(BUSINESS WIRE)--May 19, 2020--
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be participating in the Maxim Group and M-Vest COVID-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing on May 27, 2020 at 10:00 am Eastern Time. Interested investors can access the discussion as part of the Maxim Group and M-Vest COVID-19 Virtual Conference Series.
The archived discussion will be posted on the Events and Presentations section of Lineage’s website the day following the event and will be available for 30 days. Additional videos are available on the Media page of the Lineage website, located at www.lineagecell.com/media/.
About the Maxim Group and M-Vest COVID-19 Virtual Conference Series
The unmet need in infectious diseases cannot be overstated and COVID-19 continues to be a stark reminder of how unprepared the world is to deal with a pandemic. SARS-CoV-2, the virus that causes COVID-19, while sadly is still inducing tremendous loss of life, has brought out the very best in the biotechnology community from a drug, vaccine and testing perspective. In this iteration of our ongoing M-Vest Infectious Disease Virtual Conference Series, we focus in on two key areas related to the ongoing pandemic; cell based therapies and testing. Please join us as we break it down with two panels of companies leading efforts in cell therapies and testing for COVID-19.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, in clinical development for the treatment of non-small cell lung cancer and preclinical development for additional cancers and COVID-19. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005287/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa
Source: Lineage Cell Therapeutics, Inc.